← All trials
NCT04631484
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Oct 8, 2020
- Primary completion
- Sep 16, 2022
- Completion date
- Dec 16, 2022
- First posted
- Nov 17, 2020
- Last posted
- Nov 17, 2020
- Enrollment
- 320
- Arms / groups
- 2 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Polysan, Ltd.Lead sponsor
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.